drugset / Trial / NCT05652686
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in combination with chemotherapy.
Timeline
- Start
- 2023-09-05
- Primary completion
- 2027-12
- Completion
- 2028-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peluntamig | Unknown | — | — |
| Background | Atezolizumab | Monoclonal antibody | — | — |
| Background | Carboplatin | Small molecule | — | — |
| Background | Etoposide | Small molecule | — | — |
| Background | Irinotecan | Small molecule | — | — |
| Background | Lurbinectedin | Other / unclassified | — | — |
| Background | Paclitaxel | Small molecule | — | — |
| Background | Topotecan | Small molecule | — | — |